Boston Scientific Corporation (BSX, Financial) has announced the completion of its acquisition of Axonics, Inc., a public medical technology company specializing in devices for urinary and bowel dysfunction. The acquisition, finalized on November 15, 2024, involved a purchase price of $71 per share, translating to an equity value of $3.7 billion and an enterprise value of $3.3 billion, net of cash and short-term investments acquired.
This strategic acquisition is expected to be immaterial to Boston Scientific's adjusted earnings per share for 2024 and 2025, with accretive benefits anticipated in subsequent years. However, on a GAAP basis, the transaction may be less accretive or more dilutive due to amortization expenses and acquisition-related charges.
The acquisition of Axonics aligns with Boston Scientific's commitment to expanding its portfolio in the medical technology sector, particularly in the treatment of urinary and bowel dysfunction. This move is poised to enhance the company's market position and drive long-term growth.
For more detailed insights and analysis on this acquisition, visit GuruFocus.com.
Should you invest in Boston Scientific Corp (BSX, Financial) right now? Before you do it, it’s important to understand the business profitability and stock valuations, and find out what the warning signs are about. See the in-depth Boston Scientific Corp (BSX) stock research here.
